fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Medtronic announces voluntary recall of unused Valiant Navion Thoracic stent graft system

Written by | 24 Feb 2021

Medtronic plc has voluntarily issued a global recall of unused Medtronic Valiant Navion thoracic stent graft system and informed physicians to immediately cease use of the device until… read more.

Targeted drug combination improves survival in advanced kidney cancer

Written by | 24 Feb 2021

Lenvatinib plus pembrolizumab yields better overall survival than single-agent sunitinib when given as first-line therapy in untreated patients with metastatic kidney cancer. The combination also improved progression-free survival… read more.

Pfizer and BioNTech submit COVID-19 vaccine stability data at standard freezer temperature to the FDA

Written by | 23 Feb 2021

Pfizer Inc. and BioNTech SE announced the submission of new data to the FDA demonstrating the stability of their COVID-19 vaccine when stored at -25°C to -15°C (-13°F… read more.

Investigative bimekizumab shows significant efficacy in plaque psoriasis

Written by | 23 Feb 2021

Article written by Bruce Sylvester Researchers report that patients treated with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, have achieved significant… read more.

Putting the SHAPES pilot project into action

Written by | 23 Feb 2021

Interview and article by Christine Clark Dr Maureen Spargo and Dr Nicola Goodfellow describe how SHAPES, a pan-European digital healthcare project is being put into action in Northern… read more.

FDA grants expanded approval for Entresto in heart failure – Novartis

Written by | 22 Feb 2021

The FDA has approved an expanded indication for Entresto (sacubitril/valsartan), from Novartis, to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with… read more.

Pediatric PPI use appears to raise risk of asthma

Written by | 22 Feb 2021

Article written by Bruce Sylvester Pediatric proton pump inhibitor (PPI) treatment appears to be related to an increased risk of asthma in children, researchers reported on Feb. 8…. read more.

The SHAPES pilot project

Written by | 22 Feb 2021

Interview and article written by Christine Clark With advancing age many people now look forward to a future in which digital solutions will support effective self-management and independent… read more.

WHO gives COVID-19 Vaccine AstraZeneca Emergency Use Listing for COVID-19 – AstraZeneca

Written by | 21 Feb 2021

AstraZeneca’s COVID-19 vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunisation to prevent COVID-19 in individuals 18 years of age… read more.

Aspirin preferred to prevent blood clots in children after heart surgery

Written by | 21 Feb 2021

Aspirin should be favoured over warfarin to prevent blood clotting in children who undergo a surgery that replumbs their hearts, according to a new study.

Anticoagulation appears to lower Covid-19 mortality

Written by | 20 Feb 2021

Article written by Bruve Sylvester Covid-19 patients treated with preventive blood thinning drugs (prophylactic anticoagulants) within 24 hours of admission to hospital have lower subsequent mortality than covid-19… read more.

FDA approves Libtayo as first immunotherapy indicated for patients with advanced basal cell carcinoma – Sanofi

Written by | 19 Feb 2021

The FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) from Sanofi as the first immunotherapy indicated for patients with advanced basal cell carcinoma (BCC) previously treated with a… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.